P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT ID: NCT02798120

Last Updated: 2023-05-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

601 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-12

Study Completion Date

2017-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SB204 4%

All subjects received SB204 4% once daily (QD) in this open label study. Subjects assigned to SB204 4% QD in the parent study (NI-AC301/302) continued to receive SB204 for 40 more weeks. Subjects assigned to Vehicle Gel in the parent study (NI-AC301/302) received SB204 4% QD in this open label study.

Group Type EXPERIMENTAL

SB204 4%

Intervention Type DRUG

Open label, topical SB204 4%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SB204 4%

Open label, topical SB204 4%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NVN1000

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have completed 12 weeks of treatment in NI-AC301 or NI-AC302

Exclusion Criteria

* Terminated early from an SB204 Phase 3 pivotal study for any reason
* Have an on-going adverse event at Week 12 visit for NI-AC301 or NI-AC302 that warrants stopping study drug application
* Have used medications or vitamins during the 12 weeks immediately preceding this study which were reported to exacerbate acne.
Minimum Eligible Age

9 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chiltern International Inc.

INDUSTRY

Sponsor Role collaborator

Novan, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joyce Rico

Role: STUDY_CHAIR

Novan, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CIL #138

Birmingham, Alabama, United States

Site Status

CIL #218

Mobile, Alabama, United States

Site Status

CIL #189

Phoenix, Arizona, United States

Site Status

CIL #146

Anaheim, California, United States

Site Status

CIL #139

Cerritos, California, United States

Site Status

CIL #216

Chula Vista, California, United States

Site Status

CIL #186

Fresno, California, United States

Site Status

CIL #210

Fresno, California, United States

Site Status

CIL #174

Huntington Beach, California, United States

Site Status

CIL #213

La Mesa, California, United States

Site Status

CIL #209

Oceanside, California, United States

Site Status

CIL #190

Sacramento, California, United States

Site Status

CIL #161

San Diego, California, United States

Site Status

CIL #113

San Diego, California, United States

Site Status

CIL #195

Santa Ana, California, United States

Site Status

CIL #119

Santa Monica, California, United States

Site Status

CIL #199

Santa Rosa, California, United States

Site Status

CIL #103

Boca Raton, Florida, United States

Site Status

CIL #208

Hialeah, Florida, United States

Site Status

CIL #212

Homestead, Florida, United States

Site Status

CIL #222

Lauderdale Lakes, Florida, United States

Site Status

CIL #170

Miami Lakes, Florida, United States

Site Status

CIL #204

Miami Springs, Florida, United States

Site Status

CIL #172

Orlando, Florida, United States

Site Status

CIL #185

Ormond Beach, Florida, United States

Site Status

CIL #203

Ormond Beach, Florida, United States

Site Status

CIL #110

Pinellas Park, Florida, United States

Site Status

CIL #227

Sanford, Florida, United States

Site Status

CIL #211

South Miami, Florida, United States

Site Status

CIL #176

St. Petersburg, Florida, United States

Site Status

CIL #152

Tampa, Florida, United States

Site Status

CIL #229

Tampa, Florida, United States

Site Status

CIL #144

Tampa, Florida, United States

Site Status

CIL #153

Wellington, Florida, United States

Site Status

CIL #116

Newnan, Georgia, United States

Site Status

CIL #143

Savannah, Georgia, United States

Site Status

CIL #175

New Albany, Indiana, United States

Site Status

CIL #191

Overland Park, Kansas, United States

Site Status

CIL #215

Wichita, Kansas, United States

Site Status

CIL #117

Louisville, Kentucky, United States

Site Status

CIL #194

Richmond, Kentucky, United States

Site Status

CIL #219

Monroe, Louisiana, United States

Site Status

CIL #187

St Louis, Missouri, United States

Site Status

CIL #148

Norfolk, Nebraska, United States

Site Status

CIL #140

Omaha, Nebraska, United States

Site Status

CIL #182

Las Vegas, Nevada, United States

Site Status

CIL #201

Berlin, New Jersey, United States

Site Status

CIL #141

Montclair, New Jersey, United States

Site Status

CIL #156

Albuquerque, New Mexico, United States

Site Status

CIL #108

Rochester, New York, United States

Site Status

CIL #221

Salisbury, North Carolina, United States

Site Status

CIL #169

Cincinnati, Ohio, United States

Site Status

CIL #226

Cincinnati, Ohio, United States

Site Status

CIL #237

Gresham, Oregon, United States

Site Status

CIL #200

Portland, Oregon, United States

Site Status

CIL #137

Broomall, Pennsylvania, United States

Site Status

CIL #178

Philadelphia, Pennsylvania, United States

Site Status

CIL #217

Chattanooga, Tennessee, United States

Site Status

CIL #198

Arlington, Texas, United States

Site Status

CIL #160

Austin, Texas, United States

Site Status

CIL #154

Beaumont, Texas, United States

Site Status

CIL #184

Bryan, Texas, United States

Site Status

CIL #188

Houston, Texas, United States

Site Status

CIL #151

Plano, Texas, United States

Site Status

CIL #168

Plano, Texas, United States

Site Status

CIL #224

San Antonio, Texas, United States

Site Status

CIL #106

Salt Lake City, Utah, United States

Site Status

CIL #105

Lynchburg, Virginia, United States

Site Status

CIL #231

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NI-AC303

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of a New Drug Treatment for Acne
NCT01326780 COMPLETED PHASE2